http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CA-2205315-C
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_966a6c1f382ec9bcb5e3839dfd73e5b8 |
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/Y02P20-55 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07C401-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P3-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-59 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P19-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07F7-1804 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07C401-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P43-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-59 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07F7-18 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P19-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P3-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07C49-743 |
| filingDate | 1997-05-14-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2006-10-24-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c3bf8277249b012830d21d12da3f2033 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c5dcf6262dde45278959fd0be4771505 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_9158711fb8bc3af73c36784c761af470 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_02061a6251de9d947ad7dc35313af92e |
| publicationDate | 2006-10-24-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CA-2205315-C |
| titleOfInvention | Fluorinated vitamin d3 analogs |
| abstract | The novel fluorinated Vitamin D3 analogs of formula (see formula I) wherein: X is (H, H) or =CH2; R1 and R2 are, independently of each other, hydrogen, (C1-C4) alkyl or fluoroalkyl, or R1 and R2 together with C-20 form a (C3-C6) cycloalkyl or cyclofluoroalkyl, or R1 and R2 together form =CH2; R3 and R4 are, independently of each other, a (C1-C4) alkyl or fluoroalkyl, or R3 and R4 together with C-25 form a (C3-C9) cycloalkyl or cyclofluoroalkyl; A is a single bond or a double bond; and B is a double bond or a triple bond; except that: (i) when X is =CH2, R3 and R4 are each CF3, A is a double bond and one of R1 or R2 is hydrogen, then the other of R1 or R2 cannot be CH3; (ii) when X is =CH2, R3 and R4 are each a (C1-C2) alkyl, A is a double bond and R2 is hydrogen, then R1 cannot be CH3; (iii) when X is =CH2, R3 and R4 are each a (C1-C4) alkyl, A is a double bond and R1 is hydrogen, then R2 cannot be CH3; (iv) when X is =CH2, one of R3 or R4 is a CF3, A is a double bond, R1 is CH3 and R2 is hydrogen, then the other of R3 or R4 cannot be CH3; and (v) when X is (H,H), R3 and R4 are each CF3, A is a double bond, B is a triple bond and R2 is hydrogen, then R1 cannot be CH3, and the compounds of the above formula I wherein: X i s ( H , H ) or =CH2 ; R1 and R2 are, independently of each other, hydrogen, (C1-C4) alkyl or fluoroalkyl, or R1 and R2 together with C-20 form a (C3-C6) cycloalkyl or cyclofluoroalkyl, or R1 and R2 together form =CH2; R3 and R4 are, independently of each other, a (C1-C4) alkyl or fluoroalkyl, or R3 and R4 together with C-25 form a (C3-C9) cycloalkyl or cyclofluoroalkyl; A is a single bond or a double bond; and B is a double bond or a triple bond; except that where R3 and R4 are each CF3 and A is a double bond and B is a triple bond and R2 is hydrogen, then R1 cannot be CH3, are useful in the treatment of osteoporosis. |
| priorityDate | 1996-05-23-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 143.